“A trait that is objectively tested and analyzed as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention” is the definition of a biomarker.
Testing for biomarkers is a means to find genes, proteins, and other components (also known as tumour markers or biomarkers) that can reveal cancer information. A distinct pattern of biomarkers characterizes each person’s cancer. Some biomarkers influence the efficacy of specific cancer therapies.
Biomarker testing services are known as “molecular testing” or “genetic testing.” It is carried out by taking a blood sample or a small piece of tissue (referred to as a biopsy) from the patient’s tumour. The tissue or blood sample is then sent to a lab for analysis, which can reveal details on the particular tumour makeup of the patient.
Because each person has a distinct pattern of biomarkers, choosing the best platform for biomarker validation services can be challenging.
The following actions will aid in your selection process:
1. The best course of action is to let the biomarker guide the choice: It is advisable to employ a push approach when choosing which platform to use, with the biomarker acting as the primary determinant. This is in contrast to a pull strategy, where selecting a forum would be driven more by its widespread availability rather than by how well it would generally fit the biomarker.
2. The platform choice should rely on aspects determined by the biomarker, like its sensitivity or detection method.
3. The Luminex platform is a fluorescent technique for quantifying many biomarkers in various biological matrices. More biomarkers may be quantified per sample Using this platform than with any other biomarker detection methodologies.
Must Read: The Role of PK Labs in Clinical Trial Design and Execution
4. Meso scale discovery(MSD) platform: Multiple biomarkers can be measured using an MSD ECL or electrochemiluminescence approach in a range of biological matrices. It provides the highest sensitivity and comprehensive dynamic range of all biomarker detection techniques. The MSD platform offers higher selectivity and dynamic range than other conventional photometric methods. It is a single vendor platform with proprietary instruments and microtiter plate lab equipment.
5. ELISA platform: It Uses a colourimetric approach to measure specific biomarkers in various biological matrices.
6. The most appropriate quantification platform for a particular biomarker test will rely on several variables, such as the desired selectivity and whether it can employ the actual matrix and biomarker analyte without resorting to a surrogate or combination strategy. The ability to choose from multiple analytical options in various circumstances is advantageous for the biomarker bioanalyst. It enables them to proactively address analytical issues, allowing for the production of high-quality, reliable data for internal or pivotal decision-making purposes regarding the safety or efficacy of a drug candidate throughout the drug development process overview.
7. Inorganic particles are rarely used in automated IVD lab platforms. Most IVD platforms use organic-based or polymeric organic particles. The choice of which particle to utilize will rely on many variables, including the desired biomarker sensitivity, practicability and convenience of usage, and the overall goal of the process.